Evidence
Lancet Neurol. 2023 May;22(5):430-442. doi: 10.1016/S1474-4422(23)00038-8.
ABSTRACT
Tauopathies are a heterogeneous group of neurodegenerative disorders that are characterised by the aggregation of the microtubule-associated protein tau into filamentous inclusions within neurons and glia. Alzheimer’s disease is the most prevalent tauopathy. Despite years of intense research efforts, developing disease-modifying interventions for these disorders has been very challenging. The detrimental role that chronic inflammation plays in the pathogenesis of Alzheimer’s disease is increasingly recognised; however, it is largely ascribed to the accumulation of amyloid β, leaving the effect of chronic inflammation on tau pathology and neurofibrillary tangle-related pathways greatly overlooked. Tau pathology can independently arise secondary to a range of triggers that are each associated with inflammatory processes, including infection, repetitive mild traumatic brain injury, seizure activity, and autoimmune disease. A greater understanding of the chronic effects of inflammation on the development and progression of tauopathies could help forge a path for the establishment of effective immunomodulatory disease-modifying interventions for clinical use.
PMID:37059510 | DOI:10.1016/S1474-4422(23)00038-8
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Chronic effects of inflammation on tauopathies
🌐 90 Days
VR Related Evidence Matrix
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Lateral geniculate body is spared of tau pathology in Pick disease
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
- Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Is Alzheimer disease a disease?
- Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
- Effect of Natural Osmolytes on Recombinant Tau Monomer: Propensity of Oligomerization and Aggregation
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Cortical-sparing chronic traumatic encephalopathy (CSCTE): a distinct subtype of CTE
- Cortical-sparing chronic traumatic encephalopathy (CSCTE): a distinct subtype of CTE
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Tau accumulation and its spatial progression across the Alzheimer's disease spectrum
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
- 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy
- European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Long-Term High-Fat Diet Consumption Aggravates β-Amyloid Deposition and Tau Pathology Accompanied by Microglial Activation in an Alzheimer's Disease Model
- Associations of sleep disorders with all-cause MCI/dementia and different types of dementia - clinical evidence, potential pathomechanisms and treatment options: A narrative review
- Fixel-based analysis reveals tau-related white matter changes in early stages of Alzheimer's disease
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Genomic stress and impaired DNA repair in Alzheimer disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Cross-regulation between the immune system and the extracellular matrix during lung pathology
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Edaravone Dexborneol mitigates pathology in animal and cell culture models of Alzheimer's disease by inhibiting neuroinflammation and neuronal necroptosis
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- The cultural history of dementia
- Precision proteoform design for 4R tau isoform selective templated aggregation
- Differential Regulation of Neurotrophic Factors During Pathogenic Tau-Aggregation in a Tau Transgenic Mouse Model for Alzheimer's Disease: A Protocol for Double-Labeling mRNA by In Situ Hybridization and Protein Epitopes by Immunohistochemistry
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model
- Pathogenic soluble tau peptide disrupts endothelial calcium signaling and vasodilation in the brain microvasculature
- Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19
- Social activity mediates locus coeruleus tangle-related cognition in older adults
- Influences of amyloid-beta and tau on white matter neurite alterations in dementia with Lewy bodies
- Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer's astrocytes
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study
- Neurotoxic Microglial Activation via IFNγ-Induced Nrf2 Reduction Exacerbating Alzheimer's Disease
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Generating PET scan patterns in Alzheimer's by a mathematical model
- Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems
- Identification of retinal tau oligomers, citrullinated tau, and other tau isoforms in early and advanced AD and relations to disease status
- Corpora amylacea negatively correlate with hippocampal tau pathology in Alzheimer's disease
Evidence Blueprint
Chronic effects of inflammation on tauopathies
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Chronic effects of inflammation on tauopathies
🌐 365 Days
VR Related Evidence Matrix
- Tau and Alzheimer's disease: Past, present and future
- Passive tau-based immunotherapy for tauopathies
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer's disease-related mouse models
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease
- Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
- A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
- A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury
- Lymphocyte-Activation Gene 3 Facilitates Pathological Tau Neuron-to-Neuron Transmission
- Amidst an amygdala renaissance in Alzheimer's disease
- Primary retinal tauopathy: A tauopathy with a distinct molecular pattern
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Local structural preferences in shaping tau amyloid polymorphism
- APOEε4 potentiates amyloid β effects on longitudinal tau pathology
- Lateral geniculate body is spared of tau pathology in Pick disease
- New insights into the therapeutic approaches for the treatment of tauopathies
- A new metal ion chelator attenuates human tau accumulation-induced neurodegeneration and memory deficits in mice
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
- 14-3-3 [Formula: see text]-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2
- Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease
- Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy
- Disentangling tau: One protein, many therapeutic approaches
- Structure-Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Polypathologic associations with grey matter atrophy in neurodegenerative disease
- Quantitative Assays for Catalytic Photo-Oxygenation of Alzheimer Disease-Related Tau Proteins
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease
- Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer's Disease
- Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice
- Self-Aggregating Tau Fragments Recapitulate Pathologic Phenotypes and Neurotoxicity of Alzheimer's Disease in Mice
- Tau filaments from amyotrophic lateral sclerosis/parkinsonism-dementia complex adopt the CTE fold
- Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss
- Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Tau seeding without tauopathy
- Tau here, tau there, tau almost everywhere: Clarifying the distribution of tau in the adult CNS
- Is Alzheimer disease a disease?
- FMRI Complexity Correlates with Tau-PET and Cognitive Decline in Late-Onset and Autosomal Dominant Alzheimer's Disease
- Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
- Single-molecule imaging of Tau reveals how phosphorylation affects its movement and confinement in living cells
- Relationship between the tau protein and choroid plexus volume in Alzheimer's disease
- Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease
- Effect of Natural Osmolytes on Recombinant Tau Monomer: Propensity of Oligomerization and Aggregation
- Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers
- Lamivudine (3TC), a Nucleoside Reverse Transcriptase Inhibitor, Prevents the Neuropathological Alterations Present in Mutant Tau Transgenic Mice
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Distinct tau folds initiate templated seeding and alter the post-translational modification profile
- The contribution of DNA methylation to the (dys)function of oligodendroglia in neurodegeneration
- The role of peripheral inflammatory insults in Alzheimer's disease: a review and research roadmap
- Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations